3L6R | pdb_00003l6r

The structure of mammalian serine racemase: Evidence for conformational changes upon inhibitor binding


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.70 Å
  • R-Value Free: 
    0.202 (Depositor), 0.197 (DCC) 
  • R-Value Work: 
    0.168 (Depositor), 0.154 (DCC) 

wwPDB Validation 3D Report Full Report

Validation slider image for 3L6R

This is version 1.2 of the entry. See complete history

Literature

The structure of mammalian serine racemase: evidence for conformational changes upon inhibitor binding.

Smith, M.A.Mack, V.Ebneth, A.Moraes, I.Felicetti, B.Wood, M.Schonfeld, D.Mather, O.Cesura, A.Barker, J.

(2010) J Biological Chem 285: 12873-12881

  • DOI: https://doi.org/10.1074/jbc.M109.050062
  • Primary Citation Related Structures: 
    3HMK, 3L6B, 3L6C, 3L6R

  • PubMed Abstract: 

    Serine racemase is responsible for the synthesis of D-serine, an endogenous co-agonist for N-methyl-D-aspartate receptor-type glutamate receptors (NMDARs). This pyridoxal 5'-phosphate-dependent enzyme is involved both in the reversible conversion of L- to D-serine and serine catabolism by alpha,beta-elimination of water, thereby regulating D-serine levels. Because D-serine affects NMDAR signaling throughout the brain, serine racemase is a promising target for the treatment of disorders related to NMDAR dysfunction. To provide a molecular basis for rational drug design the x-ray crystal structures of human and rat serine racemase were determined at 1.5- and 2.1-A resolution, respectively, and in the presence and absence of the orthosteric inhibitor malonate. The structures revealed a fold typical of beta-family pyridoxal 5'-phosphate enzymes, with both a large domain and a flexible small domain associated into a symmetric dimer, and indicated a ligand-induced rearrangement of the small domain that organizes the active site for specific turnover of the substrate.


  • Organizational Affiliation
    • Department of Structural Biology and Biology, Evotec, 114 Milton Park, Abingdon, Oxon OX14 4SA, United Kingdom. myron.smith@evotec.com

Macromolecule Content 

  • Total Structure Weight: 38.08 kDa 
  • Atom Count: 2,851 
  • Modeled Residue Count: 320 
  • Deposited Residue Count: 346 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Serine racemase346Homo sapiensMutation(s): 2 
Gene Names: SRR
EC: 5.1.1.18 (PDB Primary Data), 4.3.1.18 (UniProt), 4.3.1.17 (UniProt)
UniProt & NIH Common Fund Data Resources
Find proteins for Q9GZT4 (Homo sapiens)
Explore Q9GZT4 
Go to UniProtKB:  Q9GZT4
PHAROS:  Q9GZT4
GTEx:  ENSG00000167720 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ9GZT4
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Modified Residues  2 Unique
IDChains TypeFormula2D DiagramParent
LLP
Query on LLP
A
L-PEPTIDE LINKINGC14 H22 N3 O7 PLYS
MSE
Query on MSE
A
L-PEPTIDE LINKINGC5 H11 N O2 SeMET

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.70 Å
  • R-Value Free:  0.202 (Depositor), 0.197 (DCC) 
  • R-Value Work:  0.168 (Depositor), 0.154 (DCC) 
Space Group: P 21 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 54.543α = 90
b = 84.212β = 90
c = 70.376γ = 90
Software Package:
Software NamePurpose
DNAdata collection
SHELXSphasing
REFMACrefinement
d*TREKdata reduction
d*TREKdata scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2010-01-26
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2021-11-10
    Changes: Database references, Derived calculations